Formycon Highlights Greater Focus On Biosimilars As Athos Deal Completes

Anticipated Profits From Biosimilar Candidates To Expand Future Development

 
• By Chloe Kent

Formycon has completed its acquisition of Athos’ biosimilar candidates for Stelara and Lucentis, following the announcement of the deal in March.

Gloved hand holding a vial and syringe
The two biosimilars should give Formycon's biosimilar business a significant boost • Source: Shutterstock

More from Biosimilars

More from Products